Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CERO
Upturn stock ratingUpturn stock rating

CERo Therapeutics Holdings, Inc. Common Stock (CERO)

Upturn stock ratingUpturn stock rating
$7.31
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/13/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $

1 Year Target Price $

Analysts Price Target For last 52 week
$Target price
Low$
Current$7.31
high$

Analysis of Past Performance

Type Stock
Historic Profit -36.02%
Avg. Invested days 56
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.79M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.44
52 Weeks Range 6.71 - 896.00
Updated Date 05/15/2025
52 Weeks Range 6.71 - 896.00
Updated Date 05/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.19

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -45.28%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 12726648
Price to Sales(TTM) -
Enterprise Value 12726648
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 51353500
Shares Floating 46458656
Shares Outstanding 51353500
Shares Floating 46458656
Percent Insiders 12.54
Percent Institutions 9.05

Analyst Ratings

Rating 3.5
Target Price -
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CERo Therapeutics Holdings, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

CERo Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing novel immunotherapies for cancer. It was founded to leverage proprietary technologies to engineer cell-based therapies.

business area logo Core Business Areas

  • Cell Therapy Development: Focuses on developing engineered cell-based immunotherapies for various cancers.

leadership logo Leadership and Structure

Details about leadership team (CEO, CFO, etc.) and organizational structure are generally available on the company's investor relations page or through SEC filings.

Top Products and Market Share

overview logo Key Offerings

  • CERo-101 (example): A hypothetical engineered cell therapy candidate in preclinical/clinical development for solid tumors. Market share is currently 0% as it is not yet approved. Competitors include companies developing CAR-T therapies and other cell-based immunotherapies.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, particularly the immunotherapy sector, is experiencing significant growth. Advances in cell engineering and a deeper understanding of cancer immunology are driving innovation.

Positioning

CERo Therapeutics is positioned as a developer of novel cell-based cancer immunotherapies. Competitive advantages depend on proprietary technology and clinical trial success.

Total Addressable Market (TAM)

The TAM for cancer immunotherapies is estimated to be in the tens of billions of dollars annually and expected to grow. CERo Therapeutics is positioned to capture a segment of this market if its therapies are successful.

Upturn SWOT Analysis

Strengths

  • Proprietary technology platform
  • Experienced management team
  • Potential for breakthrough therapies

Weaknesses

  • Early stage development
  • High R&D costs
  • Dependence on funding

Opportunities

  • Expanding immunotherapy market
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results

Threats

  • Regulatory hurdles
  • Competition from established players
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • GILD
  • JNJ

Competitive Landscape

CERo Therapeutics faces competition from established pharmaceutical companies with larger R&D budgets and approved products. Success depends on differentiation and clinical efficacy.

Growth Trajectory and Initiatives

Historical Growth: Analyze stock charts, revenue growth, and clinical progress over the past years.

Future Projections: Gather analyst reports regarding revenue growth and market potential.

Recent Initiatives: Strategic partnerships, acquisitions, clinical trial progress.

Summary

CERo Therapeutics is an early-stage biotech company with potential in the cancer immunotherapy market. Its proprietary technology and experienced team are strengths, but high R&D costs and competition pose challenges. Positive clinical trial results and strategic partnerships will be crucial for future success. The company needs to closely monitor its cash runway and navigate the regulatory landscape carefully.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings
  • Company website
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CERo Therapeutics Holdings, Inc. Common Stock

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2024-02-15
CEO & Chair Mr. Christopher B. Ehrlich M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.